RNA-Targeted Therapies and High-Throughput Screening Methods
Open Access
- 23 April 2020
- journal article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8)
Abstract
RNA-binding proteins (RBPs) are involved in regulating all aspects of RNA metabolism, including processing, transport, translation, and degradation. Dysregulation of RNA metabolism is linked to a plethora of diseases, such as cancer, neurodegenerative diseases, and neuromuscular disorders. Recent years have seen a dramatic shift in the knowledge base, with RNA increasingly being recognised as an attractive target for precision medicine therapies. In this article, we are going to review current RNA-targeted therapies. Furthermore, we will scrutinise a range of drug discoveries targeting protein-RNA interactions. In particular, we will focus on the interplay between Lin28 and let-7, splicing regulatory proteins and survival motor neuron (SMN) pre-mRNA, as well as HuR, Musashi, proteins and their RNA targets. We will highlight the mechanisms RBPs utilise to modulate RNA metabolism and discuss current high-throughput screening strategies. This review provides evidence that we are entering a new era of RNA-targeted medicine.Keywords
Funding Information
- University of Edinburgh (Edinburgh Global Research Scholarship, School of Biomedical Sciences Departmental Fund)
This publication has 190 references indexed in Scilit:
- Discovery of Small‐Molecule Modulators of Protein–RNA Interactions by Fluorescence Intensity‐Based Binding AssayChemBioChem, 2019
- RNA therapeutics: Identification of novel targets leading to drug discoveryJournal of Cellular Biochemistry, 2019
- Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cellsCancer Medicine, 2018
- Natural history of infantile‐onset spinal muscular atrophyAnnals of Neurology, 2017
- HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseasesGlia, 2017
- Emerging therapies and challenges in spinal muscular atrophyAnnals of Neurology, 2017
- Association Between Parkinson Disease and Risk of Cancer in TaiwanJAMA Oncology, 2015
- The RNA‐binding protein HuR/ELAVL1 regulates IFN‐β mRNA abundance and the type I IFN responseEuropean Journal of Immunology, 2015
- The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR‐21 Function by Directly Targeting Its PrecursorAngewandte Chemie International Edition, 2011
- Fluorescence Polarization (FP) Assays for Monitoring Peptide‐Protein or Nucleic Acid‐Protein BindingCurrent Protocols in Chemical Biology, 2009